卡铂联合紫杉醇治疗晚期子宫内膜癌:III期试验最终总生存与不良事件分析
GOG0209是一项III期随机非劣效开放标签试验,纳入1381例晚期或复发性子宫内膜癌患者,比较卡铂+紫杉醇(TC)与紫杉醇+多柔比星+顺铂(TAP)。结果显示TC在总生存(中位37 vs 41个月,HR 1.002,90%CI 0.9-1.12)和无进展生存(中位13 vs 14个月,HR 1.032,90%CI 0.93-1.15)上非劣效于TAP,且TC的3级及以上血小板减少、呕吐、腹泻和代谢毒性更低,但中性粒细胞减少更常见。
要点
- TC方案在OS和PFS上非劣效于TAP方案。
- TC组3级及以上血小板减少、呕吐、腹泻和代谢毒性低于TAP组。
- TC组中性粒细胞减少更常见(80% vs 52%),但发热性中性粒细胞减少两组相近(6% vs 7%)。
核心结论
- TC方案对晚期子宫内膜癌的总生存非劣效于TAP方案,已成为全球一线标准。
研究设计与样本
- GOG0209为III期随机非劣效开放标签试验,纳入1381例III期、IV期或复发性子宫内膜癌患者,体能状态0-2。
- 患者随机接受TAP(多柔比星45 mg/m2+顺铂50 mg/m2第1天,紫杉醇160 mg/m2第2天+G-CSF)或TC(紫杉醇175 mg/m2+卡铂AUC 6第1天),每21天一次,共7周期。
- 主要终点为总生存(改良意向治疗分析),次要终点包括无进展生存、健康相关生活质量和毒性。
主要发现
- 总生存中位TC组37个月,TAP组41个月(HR 1.002,90%CI 0.9-1.12),满足非劣效性。
- 无进展生存中位TC组13个月,TAP组14个月(HR 1.032,90%CI 0.93-1.15),满足非劣效性。
- TAP组3级及以上血小板减少23% vs TC组12%,呕吐7% vs 4%,腹泻6% vs 2%,代谢毒性14% vs 8%。
- TC组中性粒细胞减少80% vs TAP组52%;发热性中性粒细胞减少TC组6% vs TAP组7%。
关键数值与推荐
- 非劣效性界值未在原文摘要中报告。
临床怎么用
- TC方案可作为晚期或复发性子宫内膜癌的一线治疗选择,尤其适合不能耐受TAP毒性的患者。
局限性
- 原文摘要未报告非劣效性界值、具体生活质量数据及长期随访细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance status 0-2; and adequate renal, hepatic, and marrow function. Prior radiotherapy and/or hormonal therapy were permitted, but chemotherapy, including radiosensitization, was not. Patients were treated with doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with granulocyte colony-stimulating factor or paclitaxel 175 mg/m2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles. The primary endpoint was overall survival (OS; modified intention to treat). Progression-free survival (PFS), health-related quality of life (HRQoL), and toxicity were secondary endpoints. RESULTS: From 2003 to 2009, 1,381 women were enrolled. Noninferiority of TC to TAP was concluded for OS (median, 37 v 41 months, respectively; hazard ratio [HR], 1.002; 90% CI, 0.9 to 1.12), and PFS (median, 13 v 14 months; HR, 1.032; 90% CI, 0.93 to 1.15). Neutropenic fever was reported in 7% of patients receiving TAP and 6% of those receiving TC. Grade > 2 sensory neuropathy was recorded in 26% of patients receiving TAP and 20% receiving TC (P = .40). More grade ≥ 3 thrombocytopenia (23% v 12%), vomiting (7% v 4%), diarrhea (6% v 2%), and metabolic (14% v 8%) toxicities were reported with TAP. Neutropenia (52% v 80%) was more common with TC. Small HRQoL differences favored TC. CONCLUSION: With demonstrated noninferiority to TAP, TC is the global first-line standard for advanced endometrial cancer.
引用
- Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020. PMID: 33078978. doi:10.1200/JCO.20.01076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。